Pharmacovigilance in developing countries
Authors
Discussion
Loading...
Member takes
Implication
Policy review demonstrates need for novel funding models in developing countries, highlighting stakeholder collaboration to sustain pharmacovigilance.
Key Points
- Identify strategies to establish and sustain effective pharmacovigilance systems in resource-limited developing countries.
- Evaluated systemic and economic barriers affecting adverse drug reaction reporting across developing countries.
- Analyzed stakeholder roles and cross-sector mechanisms necessary to design sustainable financial frameworks for drug safety.
- Pharmacovigilance systems in developing nations face substantial resource deficits that compromise ongoing medicine safety surveillance.
- Sustainable operation requires active multi-stakeholder collaboration to establish innovative, non-traditional funding mechanisms.
Cite This Study
Pirmohamed et al. (2007) studied this question.